Acquired resistance to therapeutic agents is a major clinical concern in the prevention/treatment of malaria. The parasite has developed resistance to specific drugs through two mechanisms: mutations in target proteins such as dihyfdrofolate reductase and bc1 complex for antifolates and nathoquiniones respectively and alterations in parasite transporter molecules such as p-glycoprotein homologue 1 (Pgh1) and PfCRT. Alterations in the expression of Pgh1 have been associated with modified susceptibility to a range of unrelated drugs. The molecular mechanism(s) that are responsible for this phenotype are unknown. We have shown previously (25) that the anticonvulsant phenobarbitone (PB) can induce reduced susceptibility to chloroquine (CQ) in Plasmodium falciparum, and in the current study we provide the first evidence for a molecular mechanism underlying this phenomenon. We demonstrate that pre-treatment with PB can elicit decreased susceptibility to CQ in both CQ-resistant and CQ-sensitive parasite lines, and that this is associated with increased expression of the drug transporter Pgh1, but not PfCRT a gene product correlated with overt CQ resistance. Furthermore we have investigated the proximal promoter regions from both pfmdr1 and pfcrt, and identified a number of putative binding sites for nuclear receptors with sequence similarities to regions known to be activated by phenobarbitone in mammals. Whole genome analysis has revealed a putative nuclear receptor gene, providing the first evidence that nuclear-receptor mediated responses to drug exposure may be a mechanism of gene regulation in Plasmodium falciparum.
INTRODUCTION
Malaria remains one of the largest global health problems with between 1-2 million deaths each year mostly in young African children. One of the greatest challenges facing Africa and the rest of the world in the fight against malaria is drug resistance, a problem that has reduced our armoury of effective drugs to a critically small number. Chloroquine (CQ), the most widely used anti-malarial drug for many decades is now essentially useless with resistance being reported in all malaria endemic regions; indeed, it has been reported that CQ resistance (CQR) is a major factor behind the increasing burden of malaria worldwide (10) . Recent studies have implicated two genes in antimalarial drug resistance, pfcrt, which has been shown to confer resistance to CQ as well as a range of diverse structurally unrelated antimalarials (7, 8, 17, 21) and pfmdr1 which has been shown as a modulator of CQR and the basis of resistance to the quinoline methanols and related structures (28, 29, 34, 52) .
The pfcrt gene is highly polymorphic showing sequence variation at 15 positions; interestingly a lysine to threonine substitution at codon 76 (K76T) is present in all CQR isolates identified to date. Independent genetic experiments have confirmed the importance of mutations and in particular the K76T mutation in pfcrt as being responsible for the verapamil sensitive element of the CQ resistance phenotype (21, 43) . Furthermore, genetic manipulation of the expression level of PfCRT in a CQR parasite was shown to correlate with an increased susceptibility to CQ, presumably due to a reduced transport of drug through PfCRT (49) . Despite this correlation between PfCRT expression level and antimalarial drug susceptibility no evidence of altered expression of PfCRT has been identified in field isolates of P.
falciparum (5) .
The P. falciparum P-glycoprotein homologue protein (Pgh1) encoded for by pfmdr1 was identified over a decade before pfcrt (20) . Like pfcrt, there are a number of mutations in pfmdr1 that have been associated with multi-drug resistance (8) .
However, despite these earlier correlations with CQR, recent genetic studies have shown that these mutations exert a greater influence on parasite susceptibility to a range of other antimalarials including mefloquine, halofantrine and artemisinin than they do for CQ susceptibility (34, 41, 42) .
The multi-drug resistant phenotype in mammalian tumour cells involves the amplification of MDR genes and subsequent over expression of P-glycoprotein (3, 6) .
Studies in P. falciparum focused on this phenomenon and noted a correlation between pfmdr1 expression and CQR (8) . However, a number of further studies failed to corroborate this observation and since then it has been conclusively demonstrated that pfmdr1 copy number and expression of Pgh1 is more tightly associated with resistance to mefloquine than it is to CQR in field isolates and drug pressured laboratory lines (8, 27, 30, 31) .
The molecular processes that govern the changes in pfmdr1 and pfcrt expression described above are poorly understood with little known about the role of promoters, terminators and transcription factors in the regulation of gene expression.
P. falciparum promoters appear to conform to the classical eukaryotic bipartite structure consisting of a proximal promoter regulated by upstream enhancer elements (cis-acting elements) (15) , yet a classical regulatory motif, which can be identified in multiple unrelated genes, has yet to be identified (24) . In stark contrast is the wealth of information available about the role of transcription factors and promoters in gene regulation in mammals: One such example is the regulation of Phase I and II drug metabolizing enzymes and drug transporters by members of the nuclear receptor super-family, such as PXR and CAR, and their role in modulating drug resistance patterns in mammals (19, 22) . The nuclear receptor superfamily comprises 48 members in man, and acts within a hierarchical structure to co-ordinate body responses to a wide range of therapeutics, including antivirals, antifungals and antibiotics, are ligands for these receptors (1, 54) .
P. falciparum is known to possess orthologues for several nuclear receptor target genes, including CYPs, Pgp and MRP and previous work in our laboratory has shown that pre-treatment of parasite cultures with phenobarbitone, a potent inducer of CYPs and Pgp, resulted in a decreased susceptibility to CQ (26) . However, at the time of the initial observation the molecular processes that regulate drug induced changes in gene expression were unknown. We propose a novel system of nuclear receptor inducible gene regulation based on the extensively characterized human system that includes drug activation of nuclear receptors, subsequent translocation to the nucleus, resulting in the increased rate of transcription mediated by RNA polymerases and subsequent increase in transporter protein levels. (48) .
MATERIALS AND METHODS

P. falciparum
Pre-treatment with phenobarbitone
Syncronized ring-stage cultures of P. falciparum parasites were exposed to 0.1µM of phenobarbitone (PB) for a total period of 48h. Parasites were washed twice with drug free RPMI 1640 medium to remove traces of PB and samples were processed for in vitro drug susceptibility testing. To determine the effect of PB treatment on protein expression trophozoite stage parasites were exposed to 0.1µM of phenobarbitone (PB) for a total period of 48h and processed as described below.
In vitro drug susceptibility assays
The effect of PB pre-treatment on CQ sensitivity in the absence of presence of 5µM verapamil was determined from the incorporation of [ 3 H]-hypoxanthine into parasite nucleic acids (4) . IC 50 values were calculated for each assay using the four parameter logistic method (Grafit program, Erithacus software; Surrey, UK).
Analysis of Pgh1 and PfCRT expression.
Suspensions of trophozoite parasites at 10-15% parasitaemia were isolated using Chemiluminescence (ECL; Pharmacia Biotech, UK) and analysed by densitometry using the GeneTools software (Syngene, UK).
RESULTS
In vitro sensitivity testing
Pre-treatment with PB resulted in a decreased susceptibility to CQ in all parasite lines tested (figure 1). Interestingly, the two drug-selected parasites, K1AM
and K1HF, also exhibited a decreased susceptibility to CQ and had a partial return of the VP-sensitive CQR phenotype ( figure 1 ). This observation is unique and unexpected considering that the drug-selected parasite lines had lost the VP-sensitive CQR phenotype on selection for resistance to AM and HF respectively (17) . The observation that pre-treatment with PB results in an increased resistance to CQ confirm the observation of Ndifor et al., (25, 26) .
Effect of phenobarbitone on Pgh1 and PfCRT expression.
Pre-treatment with PB resulted in a marked increase in the expression of Pgh1, 
DISCUSSION
The observation that the potent anticonvulsant phenobarbitone produces a shift in the susceptibility of P. falciparum parasites to CQ was first noted by Ndifor et al., (26) . The parasite lines chosen for this study were the parental K1H6/2 and the two drug selected isolates, K1AM and K1HF (17) . All three parasite lines have previously been extensively characterised both phenotypically and genotypically with the major difference between them being the acquisition of the novel S163R mutation typically associated with CQS parasite lines (7, 17, 21, 36, 43) .
Since the incubation time was insufficient to elicit a genotypic change in the parasite, the unique pattern of changes in CQ-susceptibility produced by PB treatment suggest an adaptive response to PB. It is well known that PB induces the expression of CYPs and ABC transporter proteins in mammals via nuclear receptor dependent mechanisms (13, 14, 16, 19, 38-40, 46, 53) . The changes in CQ-susceptibility observed after PB treatment could feasibly be controlled by an increased metabolism of CQ by CYPs, a hypothesis originally put forward by Ndifor et al., (25, 26) .
However, it has been shown that CQ is not metabolised by malarial parasites (33, 47) .
We propose an alternate explanation, in keeping with the known effects of PB in other systems, that PB influences CQ-susceptibility levels by regulating the expression of drug transporter genes such as pfmdr1 and pfcrt, reducing the intracellular availability of CQ due to increased intracellular drug clearance. Such a hypothesis is supported In fact a recent study by Gunasekera et al., (11) showed that the P. falciparum genome has the capacity to respond to external stimuli by identifying a number of loci that had altered gene expression after exposure to CQ including the pfmdr1 locus: These findings corroborate the observations presented in this study and highlights the diversity of the LA-TF superfamily across species. Our proteome scan for putative nuclear receptors support such a hypothesis, identifying seven putative nuclear receptors, including potential orthologues for PPAR and the ubiquitous heterodimer partner RXR.
This study provides the first evidence of a malarial parasite drug-inducible system of gene expression that is closely related to the mechanism used in a range of evolutionary diverse classes, including mammalia, aves and chromadorea. Despite these strong similarities there are a number of components of the system that have not been identified in the malaria parasite and in order to validate this system these need to be identified and characterised (figure 4). However, we propose that the induction of Pgh1 observed after PB treatment is a direct cellular response to the drug in an attempt by the parasite to remove the drug thereby preventing toxicity. The fact that the increased expression of Pgh1 was associated with an increased resistance to CQ further adds support for the role of this protein in conferring reduced parasite susceptibility to this important antimalarial. Furthermore a preliminary analysis of the predicted parasite proteome using NuReBaSe -NUclear REceptor dataBASE falciparum multi-resistance protein 1 gene, pfmrp1. Table 2 DNA sequence and matrix similarity of transcription factors identified in pfmdr1 and pfcrt 1 Core similarity is the match against the nucleotides representing the core motif of the TF, where 1= 100% identity 2 Matrix similarity is the overall similarity to the TF binding motif, where 1= 100% identity 3 Actual DNA sequence from either the pfmdr1 or pfcrt promoter with the nucleotides in red representing critical residues for binding 
